Neurol. praxi. 2009;10(3):165-171

Cognitive dysfunction in multiple sclerosis

MUDr. Michal Dufek
Cerebrovaskulární centrum, Neurologická klinika, Fakultní nemocnice u sv. Anny, Brno

Cognitive function impairment is common in patients with multiple sclerosis. Particularly affected are attention, speed of processing of information,

and short-term memory. The cognitive deficits adversely affect social relations as well as quality of life and are the most common

cause of job loss. The severity of the cognitive deficits correlates with the pathology seen on conventional magnetic resonance imaging

(lesion extent, atrophy). Mostly mild forms are encountered, dementia is rare. Cognitive dysfunction may occur very early in the course of

the disease and does not correlate with the physical impairment or the duration of the disease. The therapeutic options are discussed.

Keywords: cognitive dysfunction, multiple sclerosis, magnetic resonance imaging, neurodegeneration, PASAT, SDMT, interferon beta, glatiramer acetate.

Published: July 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Dufek M. Cognitive dysfunction in multiple sclerosis. Neurol. praxi. 2009;10(3):165-171.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Amato MP, Ponziani G, Siracusa G, Sorbi S. Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years. Arch Neurol 2001; 58: 1602-1606. Go to original source... Go to PubMed...
    2. Amato MP, Portaccio E, Zipoli V. Are the protective treatments for cognitive decline in MS? Journal of the Neurological Sciencies. 2006; 245: 183-186. Go to original source... Go to PubMed...
    3. Barak Y, Achiron A. Effect of interferon-beta-1b on cognitive functions in multiple sclerosis. Eur Neurol 2002; 47: 11-14. Go to original source... Go to PubMed...
    4. Benedict RHB, Carone DA, Bakshi R. Correlating brain atrophy with cognitive dysfunction, mood disturbances and personality disorder in multiple sclerosis. J Neuroimaging 2004; 14: 36S-45S. Go to original source... Go to PubMed...
    5. Bermel RA, Puli SR, Rudick RA, Weinstock-Guttman B, Fisher E, Munschauer FE, Bakshi R. Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance paging T2 hypointensity. Arch Neurol, 2005; 62: 1371-1376. Go to original source... Go to PubMed...
    6. Brenk A, Laun K, Haase CG. Short-term cognitive training improves mental efficiency and mood in patients with multiple sclerosis. Eur Neurol. 2008; 60(6): 304-309. Epub 2008 Sep 27. Go to original source... Go to PubMed...
    7. Fischer JS, Priore RL, Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Goodkin DE, Granger CV, Simon JH, Grafman JH, Lezak MD, O'Reilly Hovey KM, Perkins KK, Barilla-Clark D, Schacter M, Shucard DW, Davidson AL, Wende KE, Bourdette DN, Kooijmans-Coutinho MF. Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Ann Neurol 2000; 48: 885-892. Go to original source...
    8. Fulton JC, Grossman RI, Udupa J, Mannon LJ, Grossman M, Wei L, Polansky M, Kolson DL. MR lesion load and cognitive function in patiens with relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol 1999; 20: 1951-1955.
    9. Gean-Marton AD, Vezina LG, Marton KI, Stimac GK, Peyster RG, Traveras JM, Davis KR. Abnormal corpus callosum: a sensitive and specific indicator of multiple sclerosis. Radiology 2001; 180: 215-221. Go to original source... Go to PubMed...
    10. Hildebrandt H, Lanz M, Hahn HK, Hoffmann E, Schwarze B, Schwendemann G, Kraus JA. Cognitive training in MS: effects and relation to brain atrophy. Restor Neurol Neurosci. 2007; 25(1): 33-43.
    11. Hoffmann S, Tittgemeyer M, von Cramon DY: Cognitive impairment in multiple sclerosis. Curr Opin Neurol, 2007; 20: 275-280. Go to original source... Go to PubMed...
    12. Hohol MJ, Guttmann CR, Orav J, Mackin GA, Kikinis R, Khoury SJ, Jolesz FA, Weiner HL. Serial neuropsychological assessment and magnetic resonance imaging analysis in multiple sclerosis. Arch Neurol 1997; 54: 1018-1025. Go to original source... Go to PubMed...
    13. Houtches MK, Benedict RHB, Killiany R, Sharma J, Jaisani Z, Singh B, Weinstock-Guttmann B, Guttmann CRG, Bakshi R. Thalamic atrophy and cognition in multiple sclerosis. Neurology 2007; 69: 1213-1223. Go to original source... Go to PubMed...
    14. Krupp LB, Christodoulou C, Melville P, Scherl WF, MacAllister WS, Elkins LE. Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology 2004; 63: 1579-1785. Go to original source... Go to PubMed...
    15. Kutzelnig A, Lassmann H. Cortical demyelination in multiple sclerosis: a substrate for cognitive deficit? J Neurol Sci 2006; 245: 123-126. Go to original source... Go to PubMed...
    16. Lovera JF, Frohman E, Brown T, Bandari D, Whitham R, Wild K, Bourdette D. Randromized double-blind plecebo controlled trial of memantine 10mg twice a day for three months as a treatment for cognitive impairment in multiple sclerosis. Neurology 72, 2009; March 17(Suppl4): 112-113.
    17. Martola J, Stawiarz L, Fredrikson S, Hillert J, Bergström J, Flodmark O, Kristoffersen Wiberg M: Progression of non-agerelated callosal brain atrophy in multiple sclerosis: a 9-year longitudinal MRI study representing four decades of disease development. J Neurol Neurosurg Psychiatry 2007; 78: 375-380.
    18. Mesaros S, Rocca MA, Riccitelli G, Pagani E, Rovaris M, Caputo D, Dhezzi A, Capra R, Bertolotto A, Comi G, Filippi M. Corpus callosum damage and cognitive dysfunction in benign MS. Hum Brain Mapp. 2008 Dec 9; (Epub). Go to original source... Go to PubMed...
    19. O'Brien AR, Chiaravalloti N, Goverover Y, DeLuca J. Evidenced-Based Cognitive Rehabilitation for Persons With Multiple Sclerosis: A Review of the Literature. PhDArch Phys Med Rehabil Vol 89, April 2008. Go to original source...
    20. Pelletier J, Suchet L, Witjas T, Habib M, Guttmann CR, Salamon G, Lyon-Caen O, Chérif AA. A longitudinal study of callosal atrophy and interhemispheric dysfunction in relapsingremitting multiple sclerosis. Arch Neurol 2001; 58: 105-111. Go to original source... Go to PubMed...
    21. Piras MR, Magnano I, Canu ED, Paulus KS, Satta WM, Soddu A, Conti M, Achene A, Solinas G, Aiello I: Longitudinal study of cognitive dysfunction in multiple sclerosis: neuropsychological, neuroradiological, and neurophysiological findings. J Neurol Neurosurg Psychiatry 2003 Jul; 74(7): 878-885. Go to original source... Go to PubMed...
    22. Pliskin NH, Hamer DP, Goldstein DS, Towle VL, Reder AT, Noronha A, Arnason BG. Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b. Neurology 1996 Dec; 47(6): 1463-1468. Go to original source... Go to PubMed...
    23. Rao SM, Glatt S, Hammeke TA. Chronic progressive multiple sclerosis: ralationship between cerebral ventricular size and neuropsychological impairment. Arch Neurol 1985; 42: 678-682. Go to original source... Go to PubMed...
    24. Rao SM, Leo GJ, Haughton VM, Aubin-Faubert PS, Bernardin L. Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis. Neurology 1989; 39: 161-166. Go to original source... Go to PubMed...
    25. Rao SM, Leo GJ, Bernardin L. Cognitive dysfunction in multiple sclerosis: frequency, patterns and prediction. Neurology 1991; 41: 685-691. Go to original source... Go to PubMed...
    26. Ranjeva JP, Audoin B, Au Duong MV, Confort-Gouny S, Malikova I, Viout P, Soulier E, Pelletier J, Cozzone PJ. Structural and functional surrogates of cognitive impairment at the very early stage of multiple sclerosis. J Neurol Sci. 2006; 245: 161-167. Go to original source... Go to PubMed...
    27. Rocca MA, Filippi M. Toward a better understanding of cerebral plasticity in multiple sclerosis. J Neurol Sci. 2006 May 15; 244: 1-2. Go to original source... Go to PubMed...
    28. Schvid SR, Goodman AD, Weinstein A, McDermott MP, Johnson KP. Cognitive function in relapsing multiple sclerosis: minimal changes in s 10-year clinical trial. Journal of the Nerological Sciences 2005; 255: 57-63. Go to original source...
    29. Shaygannejad V, Janghorbani M, Ashtari F, Zanjani HA, Zakizade N. Effects of rivastigmine on memory and cognition in multiple sclerosis. Can J Neurol Sci. 2008 Sep; 35(4): 476-81. Go to original source... Go to PubMed...
    30. Sperling RA, Guttmann CR, Hohol MJ, Warfield SK, Jakab M, Parente M, Diamond EL, Daffner KR, Olek MJ, Orav EJ, Kikinis R, Jolesz FA, Weiner HL. Regional magnetic resonance imaging lesion burden and cognitive function in multiple sclerosis: a longitudinal study. Arch Neurol 2001 Jan; 58(1): 115-121. Go to original source... Go to PubMed...
    31. Villoslada P, Arrondo G, Sepulcre J, Alegre M, Artieda J. Memantine induces reversible neurologic impairment in patients with MS. Neurology 2008 Dec 17. (Epub). Go to original source... Go to PubMed...
    32. Zivadinov R, Sepcic J, Nasuelli D, De Masi R, Bragadin LM, Tommasi MA, Zambito-Marsala S, Moretti R, Bratina A, Ukmar M, Pozzi-Mucelli RS, Grop A, Cazzato G, Zorzon M. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2001 Jun; 70(6): 773-780. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.